Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Novel targeted antibodies for R/R B-ALL

Yaqi Zhao • 11 Apr 2022
AACR 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Yaqi Zhao, MSc, St. Jude Children’s Research Hospital, Memphis, TN, briefly discusses how novel targeted antibodies could transform the treatment landscape for patients with B-cell acute lymphoblastic leukemia (B-ALL). Currently, the standard of care for patients with B-ALL consists of multiagent chemotherapy. However, chemotherapy provides few treatment options for patients with relapsed or refractory (R/R) disease. Several recently approved novel targeted antibody therapies, including blinatumomab and inotuzumab are promising treatment options for these patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.

More from Yaqi Zhao

Genomic determinants of response to blinatumomab
1:37
Genomic determinants of response to blinatumomab
Yaqi Zhao • 11 Apr 2022
Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALL
1:59
Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALL
Yaqi Zhao • 11 Apr 2022

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals